Back to News
Market Impact: 0.2
MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide
Source: globenewswire.com
Healthcare & Biotech
MIRA reported that oral SKNY-1 reduced weight and fat in obese mice, with favorable lean-mass and weight-regain outcomes versus semaglutide. The report is preclinical and provides no numerical effect sizes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
MIRA0.75
More News
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- ATEC Q3 2026 slides show profitability surge despite execution gaps
- West Pharma earnings show it's more than a GLP-1 play. Why we see more upside
- Linde delivers a good quarter and puts in a fix for an overhang on the stock
- Aspen Neuroscience prices IPO at $15 per share
- Aspen Neuroscience prices IPO at $15 per share on Nasdaq